Jaguar Health, Inc. (JAGX) stock
JAGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.39−0.03 (-7.14%)
Close on Nov 16, 2026Market cap $2.02MP/E –Yield –
Jaguar Health total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Jaguar Health's total debt was $1.73M at Jun 30, 2026. For fiscal 2025 it was $15.08M, down 35.8% from the year before. The highest annual figure on record is $30.99M in fiscal 2023.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.08M | -35.8% |
| FY2024 | Dec 31, 2024 | $23.50M | -24.2% |
| FY2023 | Dec 31, 2023 | $30.99M | +74.7% |
| FY2022 | Dec 31, 2022 | $17.74M | -29.1% |
| FY2021 | Dec 31, 2021 | $25.02M | +101.4% |
| FY2020 | Dec 31, 2020 | $12.42M | +2660.2% |
| FY2019 | Dec 31, 2019 | $450.00K | -96.4% |
| FY2017 | Dec 31, 2017 | $12.59M | +236.9% |
| FY2016 | Dec 31, 2016 | $3.74M | -35.6% |
| FY2015 | Dec 31, 2015 | $5.80M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.73M | -83.9% |
| Q1 FY2026 | Mar 31, 2026 | $11.08M | -39.9% |
| Q4 FY2025 | Dec 31, 2025 | $15.08M | -35.8% |
| Q3 FY2025 | Sep 30, 2025 | $7.65M | -64.7% |
| Q2 FY2025 | Jun 30, 2025 | $10.74M | -50.8% |
| Q1 FY2025 | Mar 31, 2025 | $18.43M | -15.1% |
| Q4 FY2024 | Dec 31, 2024 | $23.50M | -24.2% |
| Q3 FY2024 | Sep 30, 2024 | $21.66M | -30.5% |
| Q2 FY2024 | Jun 30, 2024 | $21.81M | +29.5% |
| Q1 FY2024 | Mar 31, 2024 | $21.72M | +23.8% |
| Q4 FY2023 | Dec 31, 2023 | $30.99M | +74.7% |
| Q3 FY2023 | Sep 30, 2023 | $31.16M | +55.7% |
| Q2 FY2023 | Jun 30, 2023 | $16.85M | -27.9% |
| Q1 FY2023 | Mar 31, 2023 | $17.54M | -29.2% |
| Q4 FY2022 | Dec 31, 2022 | $17.74M | -29.1% |
| Q3 FY2022 | Sep 30, 2022 | $20.01M | -19.7% |
| Q2 FY2022 | Jun 30, 2022 | $23.36M | -3.5% |
| Q1 FY2022 | Mar 31, 2022 | $24.78M | +2.3% |
| Q4 FY2021 | Dec 31, 2021 | $25.02M | +101.4% |
| Q3 FY2021 | Sep 30, 2021 | $24.93M | +837.1% |
| Q2 FY2021 | Jun 30, 2021 | $24.20M | +5948.8% |
| Q1 FY2021 | Mar 31, 2021 | $24.23M | +5957.5% |
| Q4 FY2020 | Dec 31, 2020 | $12.42M | +2660.2% |
| Q3 FY2020 | Sep 30, 2020 | $2.66M | -60.2% |
| Q2 FY2020 | Jun 30, 2020 | $400.00K | -94.8% |
| Q1 FY2020 | Mar 31, 2020 | $400.00K | – |
| Q4 FY2019 | Dec 31, 2019 | $450.00K | -95.8% |
| Q3 FY2019 | Sep 30, 2019 | $6.68M | -47.0% |
| Q2 FY2019 | Jun 30, 2019 | $7.76M | +330.8% |
| Q3 FY2018 | Sep 30, 2018 | $0 | -100.0% |
| Q2 FY2018 | Jun 30, 2018 | $10.77M | +223.7% |
| Q4 FY2017 | Dec 31, 2017 | $12.59M | +236.9% |
| Q3 FY2017 | Sep 30, 2017 | $1.80M | -56.3% |
| Q2 FY2017 | Jun 30, 2017 | $2.91M | -30.0% |
| Q1 FY2017 | Mar 31, 2017 | $3.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.74M | – |
| Q3 FY2016 | Sep 30, 2016 | $4.12M | – |
| Q2 FY2016 | Jun 30, 2016 | $4.15M | – |
See a number that looks wrong?